JP2020511131A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511131A5
JP2020511131A5 JP2019548664A JP2019548664A JP2020511131A5 JP 2020511131 A5 JP2020511131 A5 JP 2020511131A5 JP 2019548664 A JP2019548664 A JP 2019548664A JP 2019548664 A JP2019548664 A JP 2019548664A JP 2020511131 A5 JP2020511131 A5 JP 2020511131A5
Authority
JP
Japan
Prior art keywords
cell
cells
population
cell according
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019548664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511131A (ja
JP7098648B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/021332 external-priority patent/WO2018165291A1/en
Publication of JP2020511131A publication Critical patent/JP2020511131A/ja
Publication of JP2020511131A5 publication Critical patent/JP2020511131A5/ja
Priority to JP2022104262A priority Critical patent/JP7398518B2/ja
Application granted granted Critical
Publication of JP7098648B2 publication Critical patent/JP7098648B2/ja
Priority to JP2023204311A priority patent/JP7608580B2/ja
Priority to JP2024221238A priority patent/JP7806197B2/ja
Priority to JP2026004149A priority patent/JP2026063125A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019548664A 2017-03-08 2018-03-07 臨床のための、改変されたNK-92 haNK003細胞 Active JP7098648B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2022104262A JP7398518B2 (ja) 2017-03-08 2022-06-29 臨床のための、改変されたNK-92 haNK003細胞
JP2023204311A JP7608580B2 (ja) 2017-03-08 2023-12-04 臨床のための、改変されたNK-92 haNK003細胞
JP2024221238A JP7806197B2 (ja) 2017-03-08 2024-12-18 臨床のための、改変されたNK-92 haNK003細胞
JP2026004149A JP2026063125A (ja) 2017-03-08 2026-01-14 臨床のための、改変されたNK-92 haNK003細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762468890P 2017-03-08 2017-03-08
US62/468,890 2017-03-08
PCT/US2018/021332 WO2018165291A1 (en) 2017-03-08 2018-03-07 MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022104262A Division JP7398518B2 (ja) 2017-03-08 2022-06-29 臨床のための、改変されたNK-92 haNK003細胞

Publications (3)

Publication Number Publication Date
JP2020511131A JP2020511131A (ja) 2020-04-16
JP2020511131A5 true JP2020511131A5 (cg-RX-API-DMAC7.html) 2021-04-08
JP7098648B2 JP7098648B2 (ja) 2022-07-11

Family

ID=63446373

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019548664A Active JP7098648B2 (ja) 2017-03-08 2018-03-07 臨床のための、改変されたNK-92 haNK003細胞
JP2022104262A Active JP7398518B2 (ja) 2017-03-08 2022-06-29 臨床のための、改変されたNK-92 haNK003細胞
JP2023204311A Active JP7608580B2 (ja) 2017-03-08 2023-12-04 臨床のための、改変されたNK-92 haNK003細胞
JP2024221238A Active JP7806197B2 (ja) 2017-03-08 2024-12-18 臨床のための、改変されたNK-92 haNK003細胞
JP2026004149A Pending JP2026063125A (ja) 2017-03-08 2026-01-14 臨床のための、改変されたNK-92 haNK003細胞

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2022104262A Active JP7398518B2 (ja) 2017-03-08 2022-06-29 臨床のための、改変されたNK-92 haNK003細胞
JP2023204311A Active JP7608580B2 (ja) 2017-03-08 2023-12-04 臨床のための、改変されたNK-92 haNK003細胞
JP2024221238A Active JP7806197B2 (ja) 2017-03-08 2024-12-18 臨床のための、改変されたNK-92 haNK003細胞
JP2026004149A Pending JP2026063125A (ja) 2017-03-08 2026-01-14 臨床のための、改変されたNK-92 haNK003細胞

Country Status (9)

Country Link
US (5) US10801013B2 (cg-RX-API-DMAC7.html)
EP (1) EP3592845A4 (cg-RX-API-DMAC7.html)
JP (5) JP7098648B2 (cg-RX-API-DMAC7.html)
KR (4) KR102769529B1 (cg-RX-API-DMAC7.html)
CN (2) CN116440293A (cg-RX-API-DMAC7.html)
AU (2) AU2018231193B2 (cg-RX-API-DMAC7.html)
CA (1) CA3053252C (cg-RX-API-DMAC7.html)
IL (3) IL326426A (cg-RX-API-DMAC7.html)
WO (1) WO2018165291A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018231193B2 (en) 2017-03-08 2021-07-22 Immunitybio, Inc. Modified NK-92 haNK003 cells for the clinic
KR102907902B1 (ko) 2018-08-01 2026-01-02 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템
KR20200119892A (ko) * 2018-10-31 2020-10-20 난트퀘스트, 인크. Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거(elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells)
AU2019388876A1 (en) * 2018-11-26 2021-05-20 Immunitybio, Inc. IL-2 Dependent NK-92 cells with stable Fc receptor expression
WO2020205100A1 (en) * 2019-03-15 2020-10-08 Nantcell, Inc. Recombinant eril-15 nk cells
US20220265716A1 (en) * 2019-07-26 2022-08-25 Nantkwest, Inc. Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis
AU2020387167B2 (en) * 2019-11-20 2024-10-24 Immunitybio, Inc. Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
WO2021116913A1 (en) * 2019-12-09 2021-06-17 Nantkwest, Inc. Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
KR102594083B1 (ko) 2020-07-07 2023-10-25 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
EP4232567A1 (en) * 2020-10-26 2023-08-30 Shoreline Biosciences, Inc. Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells
CN114807237A (zh) * 2022-05-12 2022-07-29 广东普罗凯融生物医药科技有限公司 一种过表达CD16a的NK细胞的制备方法及其应用
EP4548096A1 (en) * 2022-06-28 2025-05-07 Cellply S.R.L. Method for the characterization of products for cell therapy
US12681020B2 (en) * 2024-03-20 2026-07-14 Immunitybio, Inc. Compositions and methods for NK-92 cells expressing native CD16

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006241A1 (en) * 1995-08-04 1997-02-20 The General Hospital Corporation Transgenic swine and swine cells having human hla genes
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
US8034332B2 (en) * 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
CA2289915A1 (en) * 1997-04-30 1998-11-05 Hans Klingemann Natural killer cell lines and methods of use
DE69834257T2 (de) 1997-04-30 2007-01-04 Klingemann, Hans Natürliche killerzelllinien und verfahren zu ihrer verwendung
ES2678094T3 (es) 2004-07-10 2018-08-08 Fox Chase Cancer Center Líneas de células asesinas naturales genéticamente modificadas
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
CN114533867A (zh) * 2015-03-27 2022-05-27 免疫生物公司 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体
ES2958720T3 (es) 2015-06-10 2024-02-13 Immunitybio Inc Células NK-92 modificadas para tratar el cáncer
AU2018231193B2 (en) 2017-03-08 2021-07-22 Immunitybio, Inc. Modified NK-92 haNK003 cells for the clinic

Similar Documents

Publication Publication Date Title
Barczak et al. Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response
CN105658789B (zh) 干细胞微粒和miRNA
ES2927175T3 (es) Método de producción de micropartículas
ES2705052T5 (es) Micropartículas de células madre y ARNmi
SG11202111401RA (en) Methods and compositions for editing rnas
CN115651927A (zh) 编辑rna的方法和组合物
CN118389602B (zh) 经人工操纵的免疫细胞
CN104703609A (zh) 干细胞微粒
WO2018083700A1 (en) Mesenchymal stem cells populations, their products, and use thereof
US20210355443A1 (en) Methods for production of tissue resident memory-like t cells and use thereof
CN104321062A (zh) 干细胞微粒
CN108026526A (zh) 用于改善移植的crispr/cas相关方法和组合物
JP2016514953A (ja) テロメア伸長に関する化合物、組成物、方法及びキット
WO2007099534A3 (en) Compostions and populations of cells obtained from the umbilical cord and methods of producing the same
US12492386B2 (en) Methods to enrich genetically engineered T cells
JP2024512608A5 (cg-RX-API-DMAC7.html)
Xiao et al. Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity
DE60334382D1 (de) Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
EP4423280A1 (en) Method for repairing hair cycle-related genes and method for treating hair cycle-related diseases using mir-520d-5p
IL138615A0 (en) Alphaviral gene expression system and dna molecules for use therein
CN119836571A (zh) 用于调节遗传驱动因子的组合物和方法
Walters et al. Divergent functions of histone acetyltransferases KAT2A and KAT2B in keratinocyte self-renewal and differentiation
US20240024373A1 (en) Method to Improve Therapeutic Properties of Stem Cells
Cheng et al. Canonical Wnt Pathway Enhanced Dental Pulp Mesenchymal Stem Cells‐Mediated Cementum Regeneration
EP3521428A1 (en) PROMOTER OF Hspa5 GENE